Investor Relations

Analyst Coverage
Firm
Analyst
Leerink Partners
David R. Risinger, CFA
(646) 338-4087
david.risinger@leerink.com
Guggenheim Securities, LLC
Seamus Fernandez
617-859-4637
seamus.fernandez@guggenheimpartners.com
William Blair
Matt Phipps, Ph.D.
Phone: 312-364-8602
Email: mphipps@williamblair.com
ROTH-MKM
Jonathan Aschoff, Ph.D.
Phone: 646-616-2795
Email:
Tenax Therapeutics is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Tenax Therapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Tenax Therapeutics or its management. Tenax Therapeutics does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Tenax Therapeutics

A Phase 3, development-stage pharmaceutical company focused on developing and commercializing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with a current focus on pulmonary hypertension.